comparemela.com

Latest Breaking News On - Generics and biosimilars - Page 1 : comparemela.com

Ireland s wide use of unlicensed medicines raises safety concerns – POLITICO

The practice has become endemic in Ireland but it doesn’t come without risks.

Meps olivier hosletVincenzo salvatoreAris messinisSusan odwyerIrish pharmacy unionA commissionBureau of investigative journalismEuropean commissionEuropean medicines agencyIrish pharmacy union odwyerHealth protection regulatory agencySusano dwyerInvestigative journalismEuropean good distributionGood manufacturing practicesDrug and device safety

Biosimilar matters

Why we should stop devaluing biosimilar medicines at all costs.

United statesEuropean medicines agencyVoluntary schemeBranded medicines pricingFrench social security finance billAid and developmentBusiness and competitionClinical trialsCompetition antitrustDrug and device safetyFinance and bankingGenerics and biosimilarsHealth careRaw materialsSupply chainsUnited kingdom

After a 70-year wait, will Europe s new patent system be a total flop? – POLITICO

The unitary patent system launches on Thursday but more than 400,000 patents have been opted out.

United statesFrance generalMike saxPaul englandChristophe archambaultChristopher thornhamSergio napolitanoMyles jelfTaylor wessingGreg bakerEuropean patent officeApp associationPatent courtUnified patent courtBig pharmaMedicines law

How China could choke EU supply of medicines

Europe relies on China for the production of certain key drugs such as antibiotics.

Primorskiy krayTaiwan straitTaiwan generalRoberta pizzocaroEurope chipsactMaggie saykaliGian paolo negrisoliEuropean commissionFlamma groupEuropean fine chemicals groupFlamma group everyoneTaiwan theMedicines actBusiness and competitionDrug and device safetyDrug shortages

EU capitals propose Chips Act for medicines

Countries are concerned by the concentration of pharmaceutical production in China.

Czech republicEuropean medicines agencyEuropean commissionEuropean chips actCritical raw materialsDrug and device safetyDrug shortagesGenerics and biosimilarsRaw materialsSupply chains

vimarsana © 2020. All Rights Reserved.